Eli Lilly and Co

📅 Upcoming

🕒 Recent(90d)

News

• Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks
  Eli Lilly first linked up with Gate Bioscience in July 2025 to leverage the biotech’s “Molecular Gate” engine to treat diseases with high unmet need. Monday’s expansion will add one undisclosed tar…
  biospace · 11h ago
• Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
  The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medi…
  biopharma_dive · 12h ago
• Foghorn cuts 40% of workforce
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 3d ago
• STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
  The U.S. approved 10 drugmakers to participate in a 340B pilot program that will allow them to offer rebates, instead of upfront discounts, to certain providers
  stat · 3d ago
• 3 takeaways from a European obesity scientific meeting
  Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…
  biopharma_dive · 4d ago
• Foghorn lays off 40% of staff after Lilly collaboration ends
  Foghorn Therapeutics and Eli Lilly teamed up in 2021 to develop and commercialize oncology products. The biotech’s layoffs will leave the company with 65 employees as it refocuses on its proprietar…
  biospace · 4d ago
• M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
  After a frantic second quarter, M&A steadied with just under $30 billion across 22 total transactions, according to a BioSpace analysis.
  biospace · 4d ago
• The top 12 companies hiring in biopharma now
  Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
  biospace · 4d ago
• Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
  EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and ty…
  biospace · 5d ago
• Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
  Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive p…
  biospace · 5d ago